Efficacy News and Research

RSS

Study finds higher readmission rates for same-day total joint replacement surgery

As the effectiveness of anesthesia, pain management and rehabilitation continues to improve, more orthopaedic procedures are being done on an outpatient basis. In a new research study presented today at the 2014 Annual Meeting of the American Academy of Orthopaedic Surgeons, same-day total joint replacement (TJR) patient outcomes were comparable to those of patients admitted to the hospital and staying at least one night following surgery.

14 Mar 2014

UC Davis MIND Institute named Intellectual and Developmental Disabilities Research Center

The UC Davis MIND Institute has been named an Intellectual and Developmental Disabilities Research Center, through a prestigious grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health - a distinction held by only a handful of neurodevelopmental centers nationwide committed to the diagnosis, prevention, treatment and amelioration of developmental disorders such as autism, fragile X syndrome and Down syndrome.

14 Mar 2014

MD Anderson collaborates with MedImmune to develop therapies that unleash patients' immune systems to attack cancers

The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson's Moon Shots Program to develop therapies that unleash patients' immune systems to attack their cancers.

14 Mar 2014

Researchers find effective strategy to eliminate cancer stem-like cells

Combining nanodrug-based chemotherapy and cryoablation provides an effective strategy to eliminate cancer stem-like cells (CSCs) the root of cancer resistance and metastasis, which will help to improve the safety and efficacy of treating malignancies that are refractory to conventional therapies.

14 Mar 2014

FDA approves expansion of BIOTRONIK's ongoing ProMRI trial

BIOTRONIK, a leading manufacturer of cardiovascular medical devices, announced today that the Food and Drug Administration has approved the expansion of BIOTRONIK's ongoing ProMRI trial. The new phase of the trial (Phase C) will study the company's ProMRI technology in implantable cardioverter-defibrillator (ICD) devices.

14 Mar 2014

TFDA approves TaiGen's Taigexyn NDA for treatment of community-acquired bacterial pneumonia

TaiGen Biotechnology Company, Limited today announced that the Taiwan Food and Drug Administration has approved the new drug application (NDA) of Taigexyn (nemonoxacin) oral formulation (500 mg) for the treatment of community-acquired bacterial pneumonia (CAP). With this NDA approval, Taiwan is the first region to grant marketing approval to Taigexyn.

13 Mar 2014

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

PhotoMedex, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

Investigators urge drug regulators to provide clear evidence on statins’ side effects

At a time when the wider prescription of statins is under renewed public scrutiny, a substantial analysis of placebo-controlled randomised trials of statins has found that only a small minority of side effects reported by those taking the cholesterol-lowering drugs are actually attributable to them.

13 Mar 2014

Notre Dame biologists awarded $23M research grant to prevent malaria and dengue fever

Notre Dame biologists Nicole Achee and Neil Lobo are leaders of an international $23 million research grant from the Bill & Melinda Gates Foundation. Their five-year project will generate the data required to show the effectiveness of a new paradigm in mosquito control -spatial repellency - for the prevention of two important mosquito-borne diseases: malaria and dengue fever.

13 Mar 2014

Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Tumor necrosis factor inhibitors (TNFis) are used to treat inflammatory conditions, such as RA. These agents work by blocking TNF, an important mediator of inflammation in RA, in order to help reduce inflammation and stop disease progression.

12 Mar 2014

Viewpoints: Exploiting botched exchanges; falling number of uninsured; Medicare drug plan retreat

Now that the badly botched rollout of the federal government's health care website seems to be behind us, Republicans have shifted their criticisms to several states that are experiencing problems enrolling people on their state-run exchanges.

12 Mar 2014

Study finds comparable outcomes for two commonly used procedures to treat pelvic organ prolapse

Two common procedures to treat pelvic organ prolapse without vaginal mesh are comparable in safety and efficacy, according to research published in the latest issue of the Journal of the American Medical Association. Researchers also found that behavioral and pelvic floor muscle therapy (BPMT) did not improve urinary incontinence or prolapse symptoms in affected women.

11 Mar 2014

Innovative study uses pharmacogenomic test to treat patients with psychotic disorders

ValueOptions, Inc. a health improvement company specializing in mental and emotional well-being and recovery, and Genomind, a personalized medicine company, today announced an innovative study that uses pharmacogenomic testing to treat patients diagnosed with psychotic disorders, including schizophrenia and bipolar disorder.

11 Mar 2014

Rexahn reports initial results from Supinoxin Phase I trial in patients with solid cancer tumors

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of SupinoxinTM (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors.

11 Mar 2014

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative today announced that Synta's lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).

11 Mar 2014

Controlled TB vaccine trial designed to study prevention of Mtb infection by vaccination

Aeras today announced the initiation of the first randomized, controlled tuberculosis (TB) vaccine trial designed to study prevention of Mycobacterium tuberculosis (Mtb) infection by vaccination.

11 Mar 2014

Researchers identify microbe that 'eats' electricity

There have been plenty of fad diets that captured the public's imagination over the years, but Harvard scientists have identified what may be the strangest of them all - sunlight and electricity.

11 Mar 2014

Homologous recombination technology for research applications in genetically modified rodents: an interview with Alexandre Fraichard, CEO, genOway

Homologous recombination is a technology that enables the targeted insertion of nucleotide fragments into the genome of a cell. It is called ‘homologous’ because it uses a sequence that is a homologue to the sequence being targeted in a gene, so that the sequence is recognized.

10 Mar 2014

Study finds that older patients are undertreated

Older people globally are being denied proper access to cancer care, according to an editorial by Queen's University Belfast academic, Professor Mark Lawler of the Centre for Cancer Research and Cell Biology.

10 Mar 2014

A pill may provide hope to relapsed leukemia and lymphoma patients

A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma patients running out of treatment options for their aggressive, treatment-resistant disease, according to three reports published online today in Blood, the journal of the American Society of Hematology.

10 Mar 2014

Efficacy News and Research

Study finds higher readmission rates for same-day total joint replacement surgery

UC Davis MIND Institute named Intellectual and Developmental Disabilities Research Center

MD Anderson collaborates with MedImmune to develop therapies that unleash patients' immune systems to attack cancers

Researchers find effective strategy to eliminate cancer stem-like cells

FDA approves expansion of BIOTRONIK's ongoing ProMRI trial

TFDA approves TaiGen's Taigexyn NDA for treatment of community-acquired bacterial pneumonia

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

Investigators urge drug regulators to provide clear evidence on statins’ side effects

Notre Dame biologists awarded $23M research grant to prevent malaria and dengue fever

Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Viewpoints: Exploiting botched exchanges; falling number of uninsured; Medicare drug plan retreat

Study finds comparable outcomes for two commonly used procedures to treat pelvic organ prolapse

Innovative study uses pharmacogenomic test to treat patients with psychotic disorders

Rexahn reports initial results from Supinoxin Phase I trial in patients with solid cancer tumors

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Controlled TB vaccine trial designed to study prevention of Mtb infection by vaccination

Researchers identify microbe that 'eats' electricity

Homologous recombination technology for research applications in genetically modified rodents: an interview with Alexandre Fraichard, CEO, genOway

Study finds that older patients are undertreated

A pill may provide hope to relapsed leukemia and lymphoma patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News